Senseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern Time
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.
The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.
Senseonics Holdings (NYSE American: SENS), un'azienda di tecnologia medica specializzata in sistemi impiantabili a lungo termine per il monitoraggio continuo della glicemia nei pazienti diabetici, ha programmato la pubblicazione dei risultati del secondo trimestre 2025 e la conference call per il 6 agosto 2025.
I risultati finanziari saranno comunicati dopo la chiusura del mercato, seguiti da una conference call con la direzione alle 16:30 ora della costa orientale. Gli investitori potranno partecipare alla chiamata telefonicamente (USA/Canada: 1-800-225-9448, Internazionale: 1-203-518-9708, codice di accesso: SENSQ2) o tramite una webcast disponibile sul sito web delle relazioni con gli investitori della società.
Senseonics Holdings (NYSE American: SENS), una empresa de tecnología médica especializada en sistemas implantables de monitoreo continuo de glucosa a largo plazo para pacientes con diabetes, ha programado su publicación de resultados del segundo trimestre de 2025 y conferencia telefónica para el 6 de agosto de 2025.
Los resultados financieros se publicarán después del cierre del mercado, seguidos por una conferencia telefónica con la dirección a las 4:30 PM hora del Este. Los inversores pueden acceder a la llamada por teléfono (EE.UU./Canadá: 1-800-225-9448, Internacional: 1-203-518-9708, código: SENSQ2) o mediante una transmisión web disponible en el sitio web de relaciones con inversionistas de la compañía.
Senseonics Holdings (NYSE American: SENS)는 당뇨병 환자를 위한 장기 이식형 연속 혈당 모니터링 시스템을 전문으로 하는 의료기술 회사로, 2025년 2분기 실적 발표 및 컨퍼런스 콜을 2025년 8월 6일로 예정하고 있습니다.
재무 결과는 장 마감 후 발표되며, 이어서 동부 표준시 기준 오후 4시 30분에 경영진 컨퍼런스 콜이 진행됩니다. 투자자들은 전화(미국/캐나다: 1-800-225-9448, 국제: 1-203-518-9708, 비밀번호: SENSQ2) 또는 회사 투자자 관계 웹사이트에서 제공되는 웹캐스트를 통해 참여할 수 있습니다.
Senseonics Holdings (NYSE American : SENS), une entreprise de technologie médicale spécialisée dans les systèmes de surveillance continue du glucose implantables à long terme pour les patients diabétiques, a programmé la publication des résultats du deuxième trimestre 2025 et une conférence téléphonique le 6 août 2025.
Les résultats financiers seront publiés après la clôture du marché, suivis d'une conférence téléphonique de la direction à 16h30, heure de l'Est. Les investisseurs pourront accéder à l'appel par téléphone (États-Unis/Canada : 1-800-225-9448, International : 1-203-518-9708, code d'accès : SENSQ2) ou via un webcast disponible sur le site des relations investisseurs de la société.
Senseonics Holdings (NYSE American: SENS), ein Medizintechnikunternehmen, das sich auf langfristig implantierbare kontinuierliche Glukoseüberwachungssysteme für Diabetiker spezialisiert hat, hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 und eine Telefonkonferenz für den 6. August 2025 angekündigt.
Die Finanzergebnisse werden nach Börsenschluss veröffentlicht, gefolgt von einer Management-Telefonkonferenz um 16:30 Uhr Eastern Time. Investoren können über Telefon (USA/Kanada: 1-800-225-9448, international: 1-203-518-9708, Zugangscode: SENSQ2) oder über einen Webcast auf der Investor-Relations-Website des Unternehmens teilnehmen.
- None.
- None.
GERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025.
Management will hold a conference call to review the Company’s second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International), passcode SENSQ2, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
When will Senseonics (SENS) report Q2 2025 earnings?
How can I listen to the Senseonics Q2 2025 earnings call?
What does Senseonics Holdings (SENS) company do?
Where can I find the webcast of Senseonics Q2 2025 earnings call?
